Impaired deoxyribonuclease I activity in patients with inflammatory bowel diseases
Status PubMed-not-MEDLINE Language English Country United States Media print-electronic
Document type Journal Article
PubMed
21687600
PubMed Central
PMC3112520
DOI
10.4061/2011/945861
Knihovny.cz E-resources
- Publication type
- Journal Article MeSH
Background and Aims. Deoxyribonuclease I (DNaseI) is an endonuclease that facilitates chromatin breakdown and promotes susceptibility to autoimmune disorders. The aim of current study was to investigate serum DNase I activity in patients with inflammatory bowel diseases (IBD). Patients and Methods. A cohort of 110 IBD patients was evaluated, aged 35 ± 12 years, 77 with Crohn's disease (CD) and 33 with ulcerative colitis (UC). 50 SLE patients and 50 healthy blood donors were examined as control groups. Results. DNase I activity in IBD patients was significantly lower than in healthy individuals, but higher than in SLE patients (P < .0001). Patients with UC showed higher DNase I activity than CD patients, P = .21. DNase I activity in female patients with IBD was significantly lower than in males, P = .024; however, no differences in DNase I activity were found in relation to gender in healthy individuals. DNase I activity has shown a strong negative correlation with the serum concentration of anti-nucleosomal antibodies in the autoimmune (SLE + IBD) cohort, as well as in the separate IBD cohort. Conclusions. Reduced serum DNase I activity probably has pathogenetic consequences in IBD. Induction of autoantibodies towards nucleosomes could be a reflection of impaired DNase I activity.
See more in PubMed
Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. Journal of Autoimmunity. 2010;34(3):J168–J177. PubMed
Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391(6662):43–50. PubMed
Napirei M, Ricken A, Eulitz D, Knoop H, Mannherz HG. Expression pattern of the deoxyribonuclease 1 gene: lesson from the Dnase1 knockout mouse. Biochemical Journal. 2004;380(3):929–937. PubMed PMC
Lacks SA. Deoxyribonuclease I in mammalian tissues. Specificity of inhibition by actin. The Journal of Biological Chemistry. 1981;256(6):2644–2648. PubMed
Takeshita H, Yasuda T, Nakajima T, Hosomi O, Nakashima Y, Kishi K. Mouse deoxyribonuclease I (DNase I): biochemical and immunological characterization, cDNA structure and tissue distribution. Biochemistry and Molecular Biology International. 1997;42(1):65–75. PubMed
Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Möröy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nature Genetics. 2000;25(2):177–181. PubMed
Napirei M, Wulf S, Mannherz HG. Chromatin breakdown during necrosis by serum Dnase1 and the plasminogen system. Arthritis and Rheumatism. 2004;50(6):1873–1883. PubMed
Gaipl US, Sheriff A, Franz S, et al. Inefficient clearance of dying cells and autoreactivity. Current Topics in Microbiology and Immunology. 2006;305:161–176. PubMed
Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008;134(4):587–598. PubMed PMC
Martínez Valle F, Balada E, Ordi-Ros J, Vilardell-Tarres M. DNase 1 and systemic lupus erythematosus. Autoimmunity Reviews. 2008;7(5):359–363. PubMed
Martínez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A, Vilardell-Tarres M. DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. Lupus. 2009;18(5):418–423. PubMed
Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World Journal of Gastroenterology. 2006;12(38):6102–6108. PubMed PMC
Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn’s disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. Journal of Immunology. 1999;163(2):1081–1090. PubMed
Itoh J, de la Motte C, Strong SA, Levine AD, Fiocchi C. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn’s disease. Gut. 2001;49(1):35–41. PubMed PMC
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. The Canadian Journal of Gastroenterology. 2005;19(supplement A):5–36. PubMed
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism. 1997;40(9):p. 1725. PubMed
Kim I, Hur NW, Shin HD, Park BL, Cheong HS, Bae SC. Associations of DNase IV polymorphisms with autoantibodies in patients with systemic lupus erythematosus. Rheumatology. 2008;47(7):996–999. PubMed
Belguith-Maalej S, Hadj-Kacem H, Kaddour N, Bahloul Z, Ayadi H. DNase1 exon2 analysis in Tunisian patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren syndrome and healthy subjects. Rheumatology International. 2009;30(1):69–74. PubMed
Dittmar M, Bischofs C, Matheis N, Poppe R, Kahaly GJ. A novel mutation in the DNASE1 gene is related with protein instability and decreased enzyme activity in thyroid autoimmunity. Journal of Autoimmunity. 2009;32(1):7–13. PubMed
Yasutomo K, Horiuchi T, Kagami S, et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nature Genetics. 2001;28(4):313–314. PubMed
Sallai K, Nagy E, Derfalvy B, Müzes G, Gergely P. Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus erythematosus. Clinical and Diagnostic Laboratory Immunology. 2005;12(1):56–59. PubMed PMC
Urowitz MB. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with SLE. Future Rheumatology. 2007;2(2):139–141. PubMed
Amoura Z, Koutouzov S, Chabre H, et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis and Rheumatism. 2000;43(1):76–84. PubMed